Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04179175
Registration number
NCT04179175
Ethics application status
Date submitted
25/11/2019
Date registered
27/11/2019
Date last updated
30/07/2025
Titles & IDs
Public title
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
Query!
Scientific title
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa
Query!
Secondary ID [1]
0
0
2023-508956-20
Query!
Secondary ID [2]
0
0
CAIN457M2301E1
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hidradenitis Suppurativa
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - secukinumab
Treatment: Drugs - secukinumab
Active comparator: secukinumab 1 HiSCR Responder - HiSCR responder at Week 52 in core trial, secukinumab 300mg every 2 weeks
Active comparator: secukinumab 2 HiSCR Responder - HiSCR responder at Week 52 in core trial, secukinumab 300mg every 4 weeks
Placebo comparator: placebo 1 HiSCR Responder - HiSCR responder at Week 52 in core trial, placebo to secukinumab 300mg every 2 weeks
Placebo comparator: placebo 2 HiSCR Responder - HiSCR responder at Week 52 in core trial, placebo to secukinumab 300 mg every 4 weeks
Other: HiSCR non-responders - non-responder at Week 52 in core trial treatment; secukinumab 300mg every 2 weeks
Treatment: Drugs: secukinumab
secukinumab 300mg every 2 weeks
Treatment: Drugs: secukinumab
secukinumab 300mg every 4 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Time to Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders
Query!
Assessment method [1]
0
0
Loss of response was defined as: * at least a 50% increase in abscess and/or nodules (AN) count compared to the average AN count from the 3 previous visits or at Week 52, whichever is lower and the increase was at least of 3 AN. * at least a 30% increase in AN compared to the average AN count from the 3 previous visits or Week 52, whichever is lower, with an increase of at least 2 AN and a further increase in the AN count of at least 2 AN at a re-assessment visit within 2-4 weeks
Query!
Timepoint [1]
0
0
Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.
Query!
Primary outcome [2]
0
0
Incidence Rate of Participants Achieving Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders
Query!
Assessment method [2]
0
0
The incidence rate of participants achieving Loss of Response (LOR) was based on the primary estimand. * Day 1 = Date of 1st dose intake in the extension study. * Subjects at risk = Subjects who did not have LOR and were not censored before or at the start of the specified time interval. * Incidence rate (%) = (number of subjects with LOR / number of subjects at risk) x 100.
Query!
Timepoint [2]
0
0
Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.
Query!
Secondary outcome [1]
0
0
Number of Participants With Treatment Emergent Adverse Events
Query!
Assessment method [1]
0
0
To assess the long-term safety and tolerability of Secukinumab in subjects with moderate to severe hidradenitis suppurativa (HS)
Query!
Timepoint [1]
0
0
Up to 216 weeks: from randomization at the extension study (Week 52) up to Week 268. Study day is defined with respect to the core studies.
Query!
Eligibility
Key inclusion criteria
* written informed consent must be obtained before any assessment is performed
* subject must have completed the study treatment period (52 weeks) in the core studies (AIN457M2301 or AIN457M2302) and had received secukinumab treatment during Treatment Period 2
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
100
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* protocol deviation in the core study which will prevent the meaningful analysis of the extension study
* ongoing or planned use of prohibited HS or non-HS treatment
* participation in the extension could expose the subject to an undue safety risk
* current sever progressive or uncontrolled disease which renders the subject unsuitable for the study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
18/03/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
15/07/2026
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
703
Query!
Recruitment in Australia
Recruitment state(s)
ACT,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Phillip
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Benowa
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - East Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2606 - Phillip
Query!
Recruitment postcode(s) [2]
0
0
4217 - Benowa
Query!
Recruitment postcode(s) [3]
0
0
3002 - East Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Massachusetts
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Minnesota
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Missouri
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Nebraska
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Pennsylvania
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
South Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Virginia
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Buenos Aires
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Santa Fe Province
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Capital Federal
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Linz
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Vienna
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Brussels
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Ghent
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Liège
Query!
Country [26]
0
0
Bulgaria
Query!
State/province [26]
0
0
Pleven
Query!
Country [27]
0
0
Bulgaria
Query!
State/province [27]
0
0
Sofia
Query!
Country [28]
0
0
Bulgaria
Query!
State/province [28]
0
0
Stara Zagora
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Ontario
Query!
Country [30]
0
0
Colombia
Query!
State/province [30]
0
0
Atlántico
Query!
Country [31]
0
0
Croatia
Query!
State/province [31]
0
0
HRV
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Czech Republic
Query!
Country [33]
0
0
Czechia
Query!
State/province [33]
0
0
Prague 1
Query!
Country [34]
0
0
Czechia
Query!
State/province [34]
0
0
Jihlava
Query!
Country [35]
0
0
Czechia
Query!
State/province [35]
0
0
Plzen Bory
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Haute Vienne
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Val De Marne
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Antony
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Bordeaux
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Brest
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Créteil
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Lyon
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Martigues
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Montpellier
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Nantes
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Nice
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Paris
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Reims
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Rouen
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Saint-Mandé
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Saint-Priest-en-Jarez
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Toulouse
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Baden-Wurttemberg
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Saxony-Anhalt
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Berlin
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Bielefeld
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Bochum
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Erlangen
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Frankfurt
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Hamburg
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Heidelberg
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Memmingen
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
München
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Münster
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Potsdam
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Schwerin
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Würzburg
Query!
Country [68]
0
0
Greece
Query!
State/province [68]
0
0
Attica
Query!
Country [69]
0
0
Greece
Query!
State/province [69]
0
0
GR
Query!
Country [70]
0
0
Greece
Query!
State/province [70]
0
0
Athens
Query!
Country [71]
0
0
Greece
Query!
State/province [71]
0
0
Thessaloniki
Query!
Country [72]
0
0
Guatemala
Query!
State/province [72]
0
0
Guatemala City
Query!
Country [73]
0
0
Hungary
Query!
State/province [73]
0
0
Debrecen
Query!
Country [74]
0
0
Hungary
Query!
State/province [74]
0
0
Kaposvár
Query!
Country [75]
0
0
Hungary
Query!
State/province [75]
0
0
Pécs
Query!
Country [76]
0
0
India
Query!
State/province [76]
0
0
Karnataka
Query!
Country [77]
0
0
India
Query!
State/province [77]
0
0
Maharashtra
Query!
Country [78]
0
0
India
Query!
State/province [78]
0
0
National Capital Territory of Delhi
Query!
Country [79]
0
0
Israel
Query!
State/province [79]
0
0
Jerusalem
Query!
Country [80]
0
0
Israel
Query!
State/province [80]
0
0
Petah Tikva
Query!
Country [81]
0
0
Israel
Query!
State/province [81]
0
0
Ramat Gan
Query!
Country [82]
0
0
Israel
Query!
State/province [82]
0
0
Tel Aviv
Query!
Country [83]
0
0
Italy
Query!
State/province [83]
0
0
AN
Query!
Country [84]
0
0
Italy
Query!
State/province [84]
0
0
FE
Query!
Country [85]
0
0
Italy
Query!
State/province [85]
0
0
FI
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
MI
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
PI
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
RM
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Napoli
Query!
Country [90]
0
0
Japan
Query!
State/province [90]
0
0
Aichi-ken
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Chiba
Query!
Country [92]
0
0
Japan
Query!
State/province [92]
0
0
Okinawa
Query!
Country [93]
0
0
Japan
Query!
State/province [93]
0
0
Saitama
Query!
Country [94]
0
0
Japan
Query!
State/province [94]
0
0
Tokyo
Query!
Country [95]
0
0
Japan
Query!
State/province [95]
0
0
Osaka
Query!
Country [96]
0
0
Lebanon
Query!
State/province [96]
0
0
Saida
Query!
Country [97]
0
0
Lithuania
Query!
State/province [97]
0
0
LTU
Query!
Country [98]
0
0
Lithuania
Query!
State/province [98]
0
0
Vilnius
Query!
Country [99]
0
0
Malaysia
Query!
State/province [99]
0
0
Kuala Lumpur
Query!
Country [100]
0
0
Malaysia
Query!
State/province [100]
0
0
Pulau Pinang
Query!
Country [101]
0
0
Malaysia
Query!
State/province [101]
0
0
Johor Bahru
Query!
Country [102]
0
0
Mexico
Query!
State/province [102]
0
0
Jalisco
Query!
Country [103]
0
0
Mexico
Query!
State/province [103]
0
0
Nuevo León
Query!
Country [104]
0
0
Netherlands
Query!
State/province [104]
0
0
Amersfroort
Query!
Country [105]
0
0
Philippines
Query!
State/province [105]
0
0
Las Piñas
Query!
Country [106]
0
0
Philippines
Query!
State/province [106]
0
0
Makati City
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Mazowian
Query!
Country [108]
0
0
Poland
Query!
State/province [108]
0
0
Lodz
Query!
Country [109]
0
0
Poland
Query!
State/province [109]
0
0
Ossy
Query!
Country [110]
0
0
Poland
Query!
State/province [110]
0
0
Rzeszów
Query!
Country [111]
0
0
Poland
Query!
State/province [111]
0
0
Warsaw
Query!
Country [112]
0
0
Poland
Query!
State/province [112]
0
0
Wroclaw
Query!
Country [113]
0
0
Portugal
Query!
State/province [113]
0
0
Lisbon
Query!
Country [114]
0
0
Portugal
Query!
State/province [114]
0
0
Porto
Query!
Country [115]
0
0
Russia
Query!
State/province [115]
0
0
Chelyabinsk
Query!
Country [116]
0
0
Russia
Query!
State/province [116]
0
0
Kazan'
Query!
Country [117]
0
0
Russia
Query!
State/province [117]
0
0
Krasnodar
Query!
Country [118]
0
0
Russia
Query!
State/province [118]
0
0
Saint Petersburg
Query!
Country [119]
0
0
Russia
Query!
State/province [119]
0
0
Smolensk
Query!
Country [120]
0
0
Russia
Query!
State/province [120]
0
0
Yaroslavl
Query!
Country [121]
0
0
Singapore
Query!
State/province [121]
0
0
Singapore
Query!
Country [122]
0
0
Slovakia
Query!
State/province [122]
0
0
Banská Bystrica
Query!
Country [123]
0
0
Slovakia
Query!
State/province [123]
0
0
Košice
Query!
Country [124]
0
0
Slovakia
Query!
State/province [124]
0
0
Prešov
Query!
Country [125]
0
0
South Africa
Query!
State/province [125]
0
0
Gauteng
Query!
Country [126]
0
0
South Korea
Query!
State/province [126]
0
0
Seoul
Query!
Country [127]
0
0
Spain
Query!
State/province [127]
0
0
Andalusia
Query!
Country [128]
0
0
Spain
Query!
State/province [128]
0
0
Catalonia
Query!
Country [129]
0
0
Spain
Query!
State/province [129]
0
0
Madrid
Query!
Country [130]
0
0
Spain
Query!
State/province [130]
0
0
Valencia
Query!
Country [131]
0
0
Spain
Query!
State/province [131]
0
0
Alicante
Query!
Country [132]
0
0
Spain
Query!
State/province [132]
0
0
Barcelona
Query!
Country [133]
0
0
Spain
Query!
State/province [133]
0
0
Las Palmas de Gran Canaria
Query!
Country [134]
0
0
Spain
Query!
State/province [134]
0
0
Pontevedra
Query!
Country [135]
0
0
Switzerland
Query!
State/province [135]
0
0
Bern
Query!
Country [136]
0
0
Switzerland
Query!
State/province [136]
0
0
Geneva
Query!
Country [137]
0
0
Switzerland
Query!
State/province [137]
0
0
Lausanne
Query!
Country [138]
0
0
Taiwan
Query!
State/province [138]
0
0
Taipei
Query!
Country [139]
0
0
Taiwan
Query!
State/province [139]
0
0
Taoyuan District
Query!
Country [140]
0
0
Turkey (Türkiye)
Query!
State/province [140]
0
0
Turkey
Query!
Country [141]
0
0
Turkey (Türkiye)
Query!
State/province [141]
0
0
TUR
Query!
Country [142]
0
0
Turkey (Türkiye)
Query!
State/province [142]
0
0
Antalya
Query!
Country [143]
0
0
Turkey (Türkiye)
Query!
State/province [143]
0
0
Aydin
Query!
Country [144]
0
0
Turkey (Türkiye)
Query!
State/province [144]
0
0
Gaziantep
Query!
Country [145]
0
0
Turkey (Türkiye)
Query!
State/province [145]
0
0
Talas Kayseri
Query!
Country [146]
0
0
United Kingdom
Query!
State/province [146]
0
0
Devon
Query!
Country [147]
0
0
United Kingdom
Query!
State/province [147]
0
0
West Midlands
Query!
Country [148]
0
0
United Kingdom
Query!
State/province [148]
0
0
West Yorkshire
Query!
Country [149]
0
0
United Kingdom
Query!
State/province [149]
0
0
Barnsley
Query!
Country [150]
0
0
United Kingdom
Query!
State/province [150]
0
0
Bristol
Query!
Country [151]
0
0
United Kingdom
Query!
State/province [151]
0
0
London
Query!
Country [152]
0
0
United Kingdom
Query!
State/province [152]
0
0
Salford
Query!
Country [153]
0
0
Vietnam
Query!
State/province [153]
0
0
Hanoi
Query!
Country [154]
0
0
Vietnam
Query!
State/province [154]
0
0
Ho Chi Minh City
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens and to assess long-term efficacy, safety and tolerability of Secukinumab in subjects with moderate to severe hidradenitis suppurativa completing either of the 2 Phase III studies. This is an expanded access trial for the core trials CAIN457M2301 (NCT03713619) and CAIN457M2302 (NCT03713619).
Query!
Trial website
https://clinicaltrials.gov/study/NCT04179175
Query!
Trial related presentations / publications
Kimball AB, Bechara FG, Badat A, Giamarellos-Bourboulis EJ, Gottlieb AB, Jemec GBE, Reguiai Z, Villani AP, Alarcon I, Bansal A, Gasperoni F, Martin R, Paguet B, Uhlmann L, Zouater H, Ravichandran S, Alavi A. Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial. Br J Dermatol. 2025 Mar 18;192(4):629-640. doi: 10.1093/bjd/ljae469.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/75/NCT04179175/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/75/NCT04179175/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT04179175
Download to PDF